A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma. Background: BMS-754807 is a potent reversible inhibitor of IGF-1R and IR ...
A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of Neuroinflammation that, for the first time, examines in depth the role of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results